There is emerging evidence that inhibition of inflammatory pathways may represent an effective therapeutic strategy for the treatment and prevention of CVD, with several randomized trials currently underway to test various new drugs (eTable 10 in the Supplement).4,55 In the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial,56 IL1β inhibition with canakinumab lowered plasma CRP and IL6 and recurrent cardiovascular events. Here, CRP is linked to Venous thrombosis.